S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Biomea Fusion (BMEA) Stock Forecast, Price & News

-0.33 (-7.88%)
(As of 05/13/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
6,536 shs
Average Volume
138,576 shs
Market Capitalization
$112.39 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BMEA News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

About Biomea Fusion

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.


Should You Buy Biomea Fusion (BMEA) Ahead of Earnings?
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$6.16 per share


Net Income
$-41.57 million
Pretax Margin




Free Float
Market Cap
$112.39 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.71 out of 5 stars

Medical Sector

878th out of 1,403 stocks

Pharmaceutical Preparations Industry

433rd out of 667 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Biomea Fusion (NASDAQ:BMEA) Frequently Asked Questions

Is Biomea Fusion a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biomea Fusion stock.
View analyst ratings for Biomea Fusion
or view top-rated stocks.

When is Biomea Fusion's next earnings date?

Biomea Fusion is scheduled to release its next quarterly earnings announcement on Thursday, May 26th 2022.
View our earnings forecast for Biomea Fusion

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) issued its quarterly earnings results on Monday, February, 28th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06.
View Biomea Fusion's earnings history

What price target have analysts set for BMEA?

2 Wall Street analysts have issued 12 month target prices for Biomea Fusion's shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate Biomea Fusion's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 236.8% from the stock's current price.
View analysts' price targets for Biomea Fusion
or view top-rated stocks among Wall Street analysts.

Who are Biomea Fusion's key executives?
Biomea Fusion's management team includes the following people:
  • Mr. Thomas Andrew Butler, Co-Founder, Chairman & CEO (Age 41, Pay $363.15k)
  • Mr. Ramses M. Erdtmann, Co-Founder, Pres, COO & Director (Age 59, Pay $36.19k) (LinkedIn Profile)
  • Mr. Franco Valle, CFO & Principal Accounting Officer (Age 41)
  • Mr. Heow Tan, Chief Technology & Quality Officer (Age 63)
  • Van Sandwick, Director of Investor Relations & Corp. Devel.
  • Ms. Naomi Cretcher, Chief People Officer
  • Dr. Thorsten Kirschberg Ph.D., Exec. VP of Chemistry (Age 52)
  • Mr. Anthony Souza, Director & Head of Information Technology
  • Dr. Stephan Morris M.D., Chief Medical Officer
  • Ms. Terrie Phan, VP & Corp. Controller
When did Biomea Fusion IPO?

(BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO.

What is Biomea Fusion's stock symbol?

Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA."

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.86%), Vanguard Group Inc. (2.63%), Northern Trust Corp (0.57%), Charles Schwab Investment Management Inc. (0.18%), Bank of New York Mellon Corp (0.17%) and Allspring Global Investments Holdings LLC (0.12%). Company insiders that own Biomea Fusion stock include A2a Pharmaceuticals, Inc, Franco Valle, Global Healthcare Ma Cormorant and Rainer M Erdtmann.
View institutional ownership trends for Biomea Fusion

Which major investors are selling Biomea Fusion stock?

BMEA stock was sold by a variety of institutional investors in the last quarter, including Qube Research & Technologies Ltd, and Northern Trust Corp.
View insider buying and selling activity for Biomea Fusion
or view top insider-selling stocks.

Which major investors are buying Biomea Fusion stock?

BMEA stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Allspring Global Investments Holdings LLC, BlackRock Inc., Rhumbline Advisers, Bank of New York Mellon Corp, JPMorgan Chase & Co., and Charles Schwab Investment Management Inc.. Company insiders that have bought Biomea Fusion stock in the last two years include A2a Pharmaceuticals, Inc, Franco Valle, Global Healthcare Ma Cormorant, and Rainer M Erdtmann.
View insider buying and selling activity for Biomea Fusion
or or view top insider-buying stocks.

How do I buy shares of Biomea Fusion?

Shares of BMEA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomea Fusion's stock price today?

One share of BMEA stock can currently be purchased for approximately $3.86.

How much money does Biomea Fusion make?

Biomea Fusion has a market capitalization of $112.39 million. The company earns $-41.57 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Biomea Fusion have?

Biomea Fusion employs 51 workers across the globe.

What is Biomea Fusion's official website?

The official website for Biomea Fusion is www.biomeafusion.com.

How can I contact Biomea Fusion?

The company can be reached via phone at 650-980-9099 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.